Tanvex BioPharma, Inc. (6541.TW)

TWD 61.4

(-1.6%)

Total Debt Summary of Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc.'s latest annual total debt in 2023 was 1.73 Billion TWD , down -5.84% from previous year.
Tanvex BioPharma, Inc.'s latest quarterly total debt in 2024 Q2 was 1.73 Billion TWD , down -18.47% from previous quarter.
Tanvex BioPharma, Inc. reported annual total debt of 1.83 Billion TWD in 2022, up 4.56% from previous year.
Tanvex BioPharma, Inc. reported annual total debt of 1.75 Billion TWD in 2021, up 20.1% from previous year.
Tanvex BioPharma, Inc. reported quarterly total debt of 2.13 Billion TWD for 2024 Q1, up 23.1% from previous quarter.
Tanvex BioPharma, Inc. reported quarterly total debt of 1.81 Billion TWD for 2023 Q2, up 1.13% from previous quarter.

Annual Total Debt Chart of Tanvex BioPharma, Inc. (2023 - 2013)

Historical Annual Total Debt of Tanvex BioPharma, Inc. (2023 - 2013)

Year	Total Debt	Total Debt Growth
2023	1.73 Billion TWD	-5.84%
2022	1.83 Billion TWD	4.56%
2021	1.75 Billion TWD	20.1%
2020	1.46 Billion TWD	327.33%
2019	342.74 Million TWD	455.22%
2018	61.73 Million TWD	4325.09%
2017	1.39 Million TWD	-27.87%
2016	1.93 Million TWD	0.0%
2015	- TWD	-100.0%
2014	538 Thousand TWD	40.1%
2013	384 Thousand TWD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q2	1.73 Billion TWD	-18.47%
2024 Q1	2.13 Billion TWD	23.1%
2023 Q2	1.81 Billion TWD	1.13%
2023 FY	1.73 Billion TWD	-5.84%
2023 Q4	1.73 Billion TWD	-6.37%
2023 Q1	1.79 Billion TWD	-2.46%
2023 Q3	1.84 Billion TWD	1.95%
2022 Q2	1.83 Billion TWD	1.87%
2022 Q4	1.83 Billion TWD	-4.6%
2022 Q3	1.92 Billion TWD	5.07%
2022 Q1	1.8 Billion TWD	2.39%
2022 FY	1.83 Billion TWD	4.56%
2021 FY	1.75 Billion TWD	20.1%
2021 Q4	1.75 Billion TWD	-1.58%
2021 Q1	1.47 Billion TWD	0.77%
2021 Q2	1.4 Billion TWD	-5.11%
2021 Q3	1.78 Billion TWD	27.61%
2020 Q4	1.46 Billion TWD	357.13%
2020 Q1	326.98 Million TWD	-4.6%
2020 Q2	359.41 Million TWD	9.92%
2020 Q3	320.39 Million TWD	-10.85%
2020 FY	1.46 Billion TWD	327.33%
2019 Q1	420.29 Million TWD	0.0%
2019 Q2	388.66 Million TWD	-7.53%
2019 FY	342.74 Million TWD	455.22%
2019 Q4	342.74 Million TWD	-7.77%
2019 Q3	371.59 Million TWD	-4.39%
2018 Q4	- TWD	-100.0%
2018 FY	61.73 Million TWD	4325.09%
2018 Q3	4.37 Million TWD	-2.3%
2018 Q2	4.47 Million TWD	-19.74%
2018 Q1	5.57 Million TWD	299.86%
2017 Q4	1.39 Million TWD	-50.02%
2017 FY	1.39 Million TWD	-27.87%
2017 Q1	5.71 Million TWD	195.55%
2017 Q2	4.18 Million TWD	-26.75%
2017 Q3	2.79 Million TWD	-33.34%
2016 Q3	- TWD	0.0%
2016 Q1	- TWD	0.0%
2016 FY	1.93 Million TWD	0.0%
2016 Q2	- TWD	0.0%
2016 Q4	1.93 Million TWD	0.0%
2015 Q4	- TWD	0.0%
2015 Q2	1.86 Million TWD	0.0%
2015 Q1	- TWD	-100.0%
2015 FY	- TWD	-100.0%
2014 FY	538 Thousand TWD	40.1%
2014 Q4	538 Thousand TWD	0.0%
2014 Q3	- TWD	0.0%
2014 Q1	- TWD	0.0%
2013 FY	384 Thousand TWD	0.0%

Peer Total Debt Comparison of Tanvex BioPharma, Inc.

Name	Total Debt	Total Debt Difference
Apex Biotechnology Corp.	180.83 Million TWD	-857.679%
Sinphar Pharmaceutical Co.,Ltd.	1.94 Billion TWD	10.963%
Panion & Bf Biotech Inc.	727.83 Million TWD	-137.937%
Chunghwa Chemical Synthesis & Biotech Co., Ltd.	1.2 Billion TWD	-43.227%
GenMont Biotech Incorporation	58.3 Million TWD	-2870.108%
Abnova (Taiwan) Corporation	7.7 Million TWD	-22373.151%
Adimmune Corporation	3.14 Billion TWD	44.894%
Polaris Group	1.19 Billion TWD	-44.552%
Energenesis Biomedical CO.,LTD.	- TWD	-Infinity%
UnicoCell Biomed Co., Ltd.	74.32 Million TWD	-2229.917%
PELL Bio-Med Technology Co. Ltd.	172.55 Million TWD	-903.599%